High‐Performance NIR‐II Fluorescent Type I/II Photosensitizer Enabling Augmented Mild Photothermal Therapy of Tumors by Disrupting Heat Shock Proteins
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202400962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Quanheng Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), Nanjing Tech University (NanjingTech), Nanjing, 211800, China. Hauptthemen laut MEDLINE: Photosensitizing Agents, Photothermal Therapy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China, Xinjiang Uygur Autonomous Region Tianshan Youth Science and Technology Top Talents Special.
Abstract (Originalsprache)
NIR‐II fluorescent photosensitizers as phototheranostic agents hold considerable promise in the application of mild photothermal therapy (MPTT) for tumors, as the reactive oxygen species generated during photodynamic therapy can effectively disrupt heat shock proteins. Nevertheless, the exclusive utilization of these photosensitizers to significantly augment the MPTT efficacy has rarely been substantiated, primarily due to their insufficient photodynamic performance. Herein, the utilization of high‐performance NIR‐II fluorescent type I/II photosensitizer (AS2 1:4 ) is presented as a simple but effective nanoplatform derived from molecule AS2 to enhance the MPTT efficacy of tumors without any additional therapeutic components. By taking advantage of heavy atom effect, AS2 1:4 as a type I/II photosensitizer demonstrates superior efficacy in producing 1 O 2 ( 1 O 2 quantum yield = 12.4%) and O 2 •− among currently available NIR‐II fluorescent photosensitizers with absorption exceeding 800 nm. In vitro and in vivo findings demonstrate that the 1 O 2 and O 2 •− generated from AS2 1:4 induce a substantial reduction in the expression of HSP90, thereby improving the MPTT efficacy. The remarkable phototheranostic performance, substantial tumor accumulation, and prolonged tumor retention of AS2 1:4 , establish it as a simple but superior phototheranostic agent for NIR‐II fluorescence imaging‐guided MPTT of tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), Nanjing Tech University (NanjingTech), Nanjing, 211800, China.
- College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310032, China.
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia/School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, 830054, China.
ORCID-Profile: Jie Liu
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
- Xinjiang Uygur Autonomous Region Tianshan Youth Science and Technology Top Talents Special
Zitieren
APA
Jiang, Q., Li, J., Du, Z., Li, M., Chen, L., Zhang, X., Tang, X., Shen, Y., Ma, D., Li, W., Li, L., Alifu, N., Hu, Q., & Liu, J. (2024). High‐Performance NIR‐II Fluorescent Type I/II Photosensitizer Enabling Augmented Mild Photothermal Therapy of Tumors by Disrupting Heat Shock Proteins. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400962
Vancouver
Jiang Q, Li J, Du Z, Li M, Chen L, Zhang X, et al. High‐Performance NIR‐II Fluorescent Type I/II Photosensitizer Enabling Augmented Mild Photothermal Therapy of Tumors by Disrupting Heat Shock Proteins. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400962
BibTeX
@article{Jiang2024,
author = {Jiang, Quanheng and Li, Jingyu and Du, Zhong and Li, Mengyuan and Chen, Liying and Zhang, Xunwen and Tang, Xialian and Shen, Yaowei and Ma, Dalong and Li, Wen and Li, Lin and Alifu, Nuernisha and Hu, Qinglian and Liu, Jie},
title = {High‐Performance NIR‐II Fluorescent Type I/II Photosensitizer Enabling Augmented Mild Photothermal Therapy of Tumors by Disrupting Heat Shock Proteins},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202400962}
}
EUVIMED